References
- Hollnagel H. Explaining risk factors to patients during a general practice consultation. Conveying group-based epidemiological knowledge to individual patients. Scand J Prim Health Care. 1999;17:3–5.
- Smith RL. Dietary lipids and heart disease: the contriving of a relationship. Am Clin Lab. 1989;Nov:26–33.
- Skolbekken JA. Communicating the risk reduction achieved by cholesterol reducing drugs. BMJ. 1998;316:1956–1958.
- Visschers VH, Meertens RM, Passchier WW, et al. Probability information in risk communication: a review of the research literature. Risk Anal. 2009;29:267–287.
- Vine DL, Hastings GE. Ischaemic heart disease and cholesterol. Absolute risk more informative than relative risk. BMJ. 1994;308:1040, 1041.
- Thompson A, Temple NJ. The case for statins: has it really been made? J R Soc Med. 2004;97:461–464.
- Gigerenzer G, Wegwarth O, Feufel M. Misleading communication of risk. BMJ. 2010;341:c4830.
- Roberts WC. Evaluating lipid-lowering trials in the twenty-first century. Am J Cardiol. 2009;103:1325–1328.
- Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–1009.